PT - JOURNAL ARTICLE AU - Min Ji Jeon AU - Eun Sang Yu AU - Dae Sik Kim AU - Chul Won Choi AU - Ha Nui Kim AU - Jeong Ah Kwon AU - Soo-Young Yoon AU - Jung Yoon TI - Performance evaluation and clinical impact of the Oncomine Myeloid Research Assay for gene expression analysis in myeloid haematologic malignancies AID - 10.1136/jcp-2022-208425 DP - 2022 Aug 23 TA - Journal of Clinical Pathology PG - jclinpath-2022-208425 4099 - http://jcp.bmj.com/content/early/2022/08/23/jcp-2022-208425.short 4100 - http://jcp.bmj.com/content/early/2022/08/23/jcp-2022-208425.full AB - Aim Gene expression analysis facilitates the detection of diagnostic and prognostic biomarkers for myeloid haematological malignancies. The Oncomine Myeloid Research Assay (OMA; Thermo Fisher Scientific, Massachusetts, USA) provides a comprehensive analysis of gene expression of five target genes, along with gene alteration and fusion. Here, we present the performance of the OMA for gene expression analysis.Methods In total, 53 RNA samples from patients diagnosed with acute myeloid leukaemia (AML) or myelodysplastic syndrome were included. Of these 53 samples, 3 were evaluated for reproducibility and 50 were evaluated for comparison with RNA-sequencing (RNA-seq). The prognostic impact of the gene expression profile produced by both OMA and RNA-seq in AML was investigated using follow-up data from 33 patients with AML.Results The OMA showed good intrarun and interrun reproducibility. Compared with the RNA-seq results, high correlations were found in BAALC, MECOM and WT1 (all r>0.9), with moderate correlations in MYC (r=0.75, p<0.001) and SMC1A (r=0.42, p=0.002). The agreement between OMA and RNA-seq in classifying the dysregulated expression group was almost perfect, except for SMC1A (κ=0.175). Among these five genes, only BAALC showed a significant clinical impact in patients with AML. Patients with high BAALC expression showed significantly shorter overall survival based on both OMA (p=0.037) and RNA-seq (p=0.003).Conclusions OMA gene expression analysis offers reproducible and accurate gene expression data for most targeted genes and demonstrates the utility of BAALC expression as a prognostic marker in AML.All data relevant to the study are included in the article or uploaded as online supplemental information.